During the last session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 7.67 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $1.07, reflecting an intraday gain of 16.74% or $0.15. The 52-week high for the LXRX share is $2.45, that puts it down -128.97 from that peak though still a striking 73.83% gain since the share price plummeted to a 52-week low of $0.28. The company’s market capitalization is $388.60M, and the average intraday trading volume over the past 10 days was 6.62 million shares, and the average trade volume was 5.04 million shares over the past three months.
Lexicon Pharmaceuticals Inc (LXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. LXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Lexicon Pharmaceuticals Inc (LXRX) registered a 16.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 16.74% in intraday trading to $1.07, hitting a weekly high. The stock’s 5-day price performance is 21.03%, and it has moved by 39.56% in 30 days. Based on these gigs, the overall price performance for the year is 44.89%. The short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 37.56 million shares and it means that shorts have 9.39 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 82.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, LXRX is trading at a discount of -460.75% off the target high and -460.75% off the low.
While earnings are projected to return 49.60% in 2025, the next five years will return 30.30% per annum.
LXRX Dividends
Lexicon Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Lexicon Pharmaceuticals Inc insiders own 1.17% of total outstanding shares while institutional holders control 74.93%, with the float percentage being 75.82%. ARTAL GROUP S.A. is the largest shareholder of the company, while 164.0 institutions own stock in it. As of 2024-06-30, the company held over 175.1 million shares (or 56.3318% of all shares), a total value of $294.17 million in shares.
The next largest institutional holding, with 38.69 million shares, is of FMR LLC’s that is approximately 12.4462% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.99 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lexicon Pharmaceuticals Inc (LXRX) shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on May 31, 2025 indicates that Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund owns about 11.05 shares. This amounts to just over 3.04 percent of the company’s overall shares, with a $11.83 million market value. The same data shows that the other fund manager holds slightly less at 5.15, or about 1.42% of the stock, which is worth about $5.51 million.
